Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo.

Humanised monoclonal antibody to respiratory syncytial virus.

A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.

Streptococcus pneumoniae Enhances Human Respiratory Syncytial Virus Infection In Vitro and In Vivo.

Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Host response to respiratory syncytial virus infection.

A genetic model of differential susceptibility to human respiratory syncytial virus (RSV) infection.

Differential mucin expression by respiratory syncytial virus and human metapneumovirus infection in human epithelial cells.

Neonatal respiratory-syncytial-virus infection.

Evidence for an intranasal immune response to human respiratory syncytial virus infection in cynomolgus macaques.

Neonatal respiratory syncytial virus infection.

An in vitro model to study immune responses of human peripheral blood mononuclear cells to human respiratory syncytial virus infection.

Detection of antibody to bovine syncytial virus and respiratory syncytial virus in bovine fetal serum.

Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases.

Respiratory syncytial virus infection in inbred mice.

A novel host factor for human respiratory syncytial virus.

Antibody response to respiratory syncytial virus infection in children <18 months old.

Detection of antibody to respiratory syncytial virus by membrane fluorescence.

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.

Activation of human eosinophils in vitro by respiratory syncytial virus.

Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice.

Agonistic 4-1BB antibody fails to reduce disease burden during acute respiratory syncytial virus (RSV) infection.

Suggest Documents

Humanised monoclonal antibody to respiratory syncytial virus.

A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.

Streptococcus pneumoniae Enhances Human Respiratory Syncytial Virus Infection In Vitro and In Vivo.

Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Host response to respiratory syncytial virus infection.

A genetic model of differential susceptibility to human respiratory syncytial virus (RSV) infection.

Differential mucin expression by respiratory syncytial virus and human metapneumovirus infection in human epithelial cells.

Neonatal respiratory-syncytial-virus infection.

Evidence for an intranasal immune response to human respiratory syncytial virus infection in cynomolgus macaques.

Neonatal respiratory syncytial virus infection.

An in vitro model to study immune responses of human peripheral blood mononuclear cells to human respiratory syncytial virus infection.

Detection of antibody to bovine syncytial virus and respiratory syncytial virus in bovine fetal serum.

Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.

Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases.

Respiratory syncytial virus infection in inbred mice.

A novel host factor for human respiratory syncytial virus.

Antibody response to respiratory syncytial virus infection in children <18 months old.

Detection of antibody to respiratory syncytial virus by membrane fluorescence.

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.

Activation of human eosinophils in vitro by respiratory syncytial virus.

Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.

Effects of cannabinoid receptor type 2 in respiratory syncytial virus infection in human subjects and mice.

Agonistic 4-1BB antibody fails to reduce disease burden during acute respiratory syncytial virus (RSV) infection.

Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo.

Recommend Documents

Follow Us